When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities

Nora Sundahl; Silke Gillessen; Christopher Sweeney; Piet Ost

doi:10.1016/j.eururo.2020.07.029

When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities

Eur Urol. 2021 May;79(5):565-567. doi: 10.1016/j.eururo.2020.07.029. Epub 2020 Aug 23.

Authors

Nora Sundahl¹, Silke Gillessen², Christopher Sweeney³, Piet Ost⁴

Affiliations

¹ Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium; Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK. Electronic address: [email protected].
² Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Universita della Svizzera Italiana, Lugano, Switzerland; University of Bern, Bern, Switzerland; Division of Cancer Science, University of Manchester, Manchester, UK.
³ Dana-Farber Cancer Institute, Boston, MA, USA; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.

PMID: 32847699
DOI: 10.1016/j.eururo.2020.07.029

Abstract

Even though prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)-computed tomography (CT) is more accurate than conventional imaging in prostate cancer patients, its impact on patient-relevant outcomes is unknown. We argue that more evidence is required before using PSMA-PET-CT as the standard of care for staging.

Publication types

Editorial

MeSH terms

Humans
Male
Neoplasm Staging
Positron Emission Tomography Computed Tomography*
Prostatic Neoplasms* / diagnostic imaging
Prostatic Neoplasms* / pathology
Radiopharmaceuticals

Substances

Radiopharmaceuticals